Le Lézard
Classified in: Science and technology
Subject: Stock Sale/Buyback

Karooooo Ltd. Announces Launch of Secondary Public Offering of Ordinary Shares


Karooooo Ltd. ("Karooooo") today announced the commencement of an underwritten secondary public offering (the "Offering") of a number of its ordinary shares held by Isaias (Zak) Jose Calisto, Karooooo's chief executive officer (the "Selling Shareholder"), that generates $75.0 million in gross proceeds. In addition, the underwriters of the Offering will have a 30-day option to purchase up to a number of additional ordinary shares that generates $11.25 million in gross proceeds from the Selling Shareholder. The price per ordinary share will be determined following the bookbuilding process. Karooooo's ordinary shares are listed on the Nasdaq Capital Market under the symbol "KARO."

Karooooo is not selling any ordinary shares in the Offering and will not receive any of the proceeds from the sale of any ordinary shares by the Selling Shareholder, but will bear the costs associated with the sale of such shares, other than any underwriting discounts and commissions, which will be borne by the Selling Shareholder.

UBS Investment Bank and William Blair are acting as joint active lead book-running managers for the Offering. Raymond James and Standard Bank are acting as joint book-running managers for the Offering.

The Registration Statement on Form F-3 relating to these securities has been filed with the Securities and Exchange Commission (the "SEC") and was declared effective by the SEC on July 22, 2024. The Offering will be made only by means of a prospectus and an accompanying prospectus supplement. Before investing, prospective investors should read the prospectus, any accompanying prospectus supplement related to the Offering and the documents incorporated by reference therein for more complete information. Copies of these documents are available at no charge on the SEC's website at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting UBS Securities LLC at 1285 6th Ave, New York, NY 10019, or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Karooooo

Karooooo, headquartered in Singapore, is a leading global software provider in the telematics industry that offers real-time mobility and workforce data analytics solutions to simplify decision making for physical operations. Karooooo serves customers in 25 countries across five continents, supporting more than 2 million subscribers as of May 31, 2024.

SOURCE Karooooo


These press releases may also interest you

at 20:11
Report with market evolution powered by AI - The global music production software market  size is estimated to grow by USD 432.8 million from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of almost 7.7%  during the...

at 20:00
Report on how AI is driving market transformation - The global corporate training market size is estimated to grow by USD 43.86 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of  7.8%  during the forecast...

at 20:00
In Chinese culture, "HONG" means "great" or "vast," reflecting the coin's ambition to achieve substantial milestones. HONG has garnered global support through its initiatives, aspiring to become one of...

at 20:00
On 12 Feb 2025 (Singapore Time), Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international multicenter Phase...

at 19:50
Oqory, Inc., a private biopharmaceutical company dedicated to developing next-generation antibody drug conjugates (ADCs) for the treatment of cancer, today announced that Michael King, Chief Executive Officer, will present data at Oppenheimer's 35th...

at 18:59
The news release, U.S. FDA approves Celltrion's AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®, issued 30-Jan-2025 by Celltrion over PR Newswire, has been updated to ensure accuracy of the availability timing of AVTOZMA® (CT-P47,...



News published on and distributed by: